Multiple sclerosis (MS) is a complex, heterogeneous, chronic disease that requires individualised treatment throughout a person's life. The disease involves the central nervous system and disrupts the flow of information within the brain and between the brain and body, signaling unpredictable symptoms.1
Over the past four decades, Biogen has been committed to translating science to meaningful advances for the MS community. Our industry-leading portfolio of medicines — backed by established safety and efficacy profiles, ongoing investment in our products, as well as our comprehensive services and solutions — enables us to offer a broad range of options to meet the ever-evolving needs of MS patients and drive greater individualised disease management.
As MS disease management and the needs of people with MS evolve, Biogen remains focused on novel research initiatives and technological innovations to further the understanding of MS and improve health outcomes. While we focus on advancing current assets in our pipeline, we aspire to pioneer disruptive therapies for MS prevention and cure through exploration in emerging science, including novel treatment approaches such as vaccine cell-based therapies, exploring new mechanisms of remyelination and neuroprotection, and developing additional preclinical models that have enhanced translational predictability.
Stephen was 22 years old when he was diagnosed with Multiple Sclerosis (MS), a life-long autoimmune disease that damages the central nervous system (CNS). Over time, damage to the CNS can cause physical disability and impair neurological functions like motor skills, thinking and vision.
An estimated 2.8 million people live with MS worldwide2 and over 33,000 in Australia.3
More than 1.9 million people globally have been treated with a Biogen disease-modifying therapy.
For more than 25 years, we have led in the research and development of new therapies to treat MS.